Portage Biotech Inc (PRTG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Portage Biotech Inc (PRTG) has a cash flow conversion efficiency ratio of -2.245x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.56 Million) by net assets ($695.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Portage Biotech Inc market capitalisation for the company's overall valuation and market capitalisation.
Portage Biotech Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Portage Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Portage Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Portage Biotech Inc ranked by their cash flow conversion efficiency. Explore Portage Biotech Inc (PRTG) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brimstone Investment Corporation Ltd
JSE:BRT
|
0.023x |
|
STAK Inc. Ordinary Shares
NASDAQ:STAK
|
N/A |
|
Metalsgrove Mining Ltd
AU:MGA
|
-0.095x |
|
Bhandari Hosiery Exports Limited
NSE:BHANDARI
|
0.015x |
|
Guardforce AI Co Ltd
NASDAQ:GFAI
|
0.022x |
|
Melbana Energy Ltd
AU:MAY
|
-0.017x |
|
Pan Malaysia Corporation Bhd
KLSE:4081
|
0.004x |
|
EAM Solar ASA
OL:EAM
|
-0.355x |
Annual Cash Flow Conversion Efficiency for Portage Biotech Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Portage Biotech Inc from 1998 to 2025. View today's stock price for Portage Biotech Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-827.00K | $-5.46 Million | 6.605x | +253.79% |
| 2024-03-31 | $3.33 Million | $-14.30 Million | -4.295x | -2582.00% |
| 2023-03-31 | $75.39 Million | $-12.07 Million | -0.160x | -291.65% |
| 2022-03-31 | $165.43 Million | $-6.76 Million | -0.041x | -40.87% |
| 2021-03-31 | $147.60 Million | $-4.28 Million | -0.029x | -13.81% |
| 2020-03-31 | $145.64 Million | $-3.71 Million | -0.026x | -341.53% |
| 2019-03-31 | $148.56 Million | $-858.00K | -0.006x | +94.82% |
| 2018-03-31 | $9.62 Million | $-1.07 Million | -0.112x | -403.20% |
| 2017-03-31 | $59.59 Million | $-1.32 Million | -0.022x | +95.32% |
| 2016-03-31 | $12.33 Million | $-5.84 Million | -0.474x | +25.43% |
| 2015-03-31 | $4.12 Million | $-2.61 Million | -0.635x | -66.43% |
| 2014-03-31 | $5.07 Million | $-1.94 Million | -0.382x | +36.44% |
| 2013-03-31 | $2.98 Million | $-1.79 Million | -0.600x | -117.39% |
| 2012-03-31 | $4.85 Million | $-1.34 Million | -0.276x | +5.92% |
| 2011-03-31 | $8.94 Million | $-2.62 Million | -0.294x | -457.97% |
| 2010-03-31 | $6.77 Million | $-356.14K | -0.053x | +79.11% |
| 2009-03-31 | $1.14 Million | $-287.38K | -0.252x | -170.28% |
| 2008-03-31 | $5.03 Million | $-468.92K | -0.093x | -16.61% |
| 2007-03-31 | $5.74 Million | $-458.84K | -0.080x | +43.87% |
| 2006-03-31 | $4.53 Million | $-645.50K | -0.142x | +25.05% |
| 2004-03-31 | $1.69 Million | $-321.51K | -0.190x | -127.71% |
| 2003-03-31 | $-214.26K | $-146.90K | 0.686x | +101.34% |
| 2002-03-31 | $3.06K | $-156.80K | -51.310x | -7026.10% |
| 2001-03-31 | $481.93K | $-347.00K | -0.720x | -146.59% |
| 2000-03-31 | $1.60 Million | $-466.90K | -0.292x | +90.95% |
| 1999-03-31 | $106.97K | $-345.09K | -3.226x | -445.75% |
| 1998-03-31 | $-453.32K | $-422.97K | 0.933x | -- |
About Portage Biotech Inc
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor … Read more